MRVI (Maravai LifeSciences Holdings, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MRVI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Rajesh Asarpota | Chief Financial Officer | F | — | — |
| 2026-08-11 | Bernd Brust | Chief Executive Officer | F | — | — |
| 2026-08-03 | Rajesh Asarpota | Chief Financial Officer | F | — | — |
| 2026-07-10 | Bernd Brust | Chief Executive Officer | F | — | — |
| 2026-07-01 | Rajesh Asarpota | Chief Financial Officer | F | — | — |
| 2026-06-10 | KURT ORESHACK | General Counsel | Sell | — | — |
| 2026-06-10 | GREGORY T LUCIER | Director | G | — | — |
| 2026-06-10 | Bernd Brust | Chief Executive Officer | F | — | — |
| 2026-05-28 | CONSTANTINE S MIHAS | Director | A | — | — |
| 2026-05-28 | R ANDREW ECKERT | Director | A | — | — |
| 2026-05-28 | LUKE JOSEPH MARKER | Director | A | — | — |
| 2026-05-28 | GREGORY T LUCIER | Director | A | — | — |
| 2026-05-28 | SEAN LAURENCE CUNNINGHAM | Director | A | — | — |
| 2026-05-28 | John A DeFord | Director | A | — | — |
| 2026-05-28 | GREGORY T LUCIER | Director | A | — | — |
| 2026-05-28 | SUSANNAH GRAY | Director | A | — | — |
| 2026-05-22 | Christine Dolan | See Remarks | A | — | — |
| 2026-05-22 | KURT ORESHACK | General Counsel | A | — | — |
| 2026-03-17 | Christine Dolan | See Remarks | F | — | — |
| 2026-03-17 | KURT ORESHACK | General Counsel | F | — | — |
| 2026-01-20 | Christine Dolan | See Remarks | F | — | — |
| 2026-01-20 | KURT ORESHACK | General Counsel | F | — | — |
| 2025-12-09 | GREGORY T LUCIER | Director | Buy | — | — |
| 2025-11-18 | Christine Dolan | See Remarks | A | — | — |
| 2025-11-17 | Bernd Brust | Chief Executive Officer | Buy | — | — |
| 2025-11-13 | Bernd Brust | Chief Executive Officer | Buy | — | — |
| 2025-07-16 | Peter Michael Leddy | See Remarks | F | — | — |
| 2025-07-11 | GREGORY T LUCIER | Director | G | — | — |
| 2025-06-30 | Rajesh Asarpota | Chief Financial Officer | A | — | — |
| 2025-06-18 | SUSANNAH GRAY | Director | A | — | — |
| 2025-06-18 | John A DeFord | Director | A | — | — |
| 2025-06-18 | R ANDREW ECKERT | Director | A | — | — |
| 2025-06-18 | MURALI PRAHALAD | Director | A | — | — |
| 2025-06-18 | GREGORY T LUCIER | Director | A | — | — |
| 2025-06-18 | LUKE JOSEPH MARKER | Director | A | — | — |
| 2025-06-18 | Jessica Hopfield | Director | A | — | — |
| 2025-06-18 | CONSTANTINE S MIHAS | Director | A | — | — |
| 2025-06-18 | SEAN LAURENCE CUNNINGHAM | Director | A | — | — |
| 2025-06-18 | BENJAMIN JAMES DAVERMAN | Director | A | — | — |
| 2025-06-10 | Bernd Brust | Chief Executive Officer | A | — | — |
| 2025-05-28 | Kevin Herde | Chief Financial Officer | A | — | — |
| 2025-05-28 | Christine Dolan | See Remarks | A | — | — |
| 2025-03-19 | KURT ORESHACK | General Counsel | A | — | — |
| 2025-03-19 | Kevin Herde | Chief Financial Officer | F | — | — |
| 2025-03-19 | Peter Michael Leddy | See Remarks | A | — | — |
| 2025-03-19 | WILLIAM E. MARTIN III | Chief Executive Officer | A | — | — |
| 2025-03-19 | REBECCA BUZZEO | See Remarks | F | — | — |
| 2025-03-19 | Kevin Herde | Chief Financial Officer | A | — | — |
| 2025-03-19 | Peter Michael Leddy | See Remarks | F | — | — |
| 2025-03-19 | KURT ORESHACK | General Counsel | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 126,239,611 | — |
| — | Director | 123,669,196 | — |
| — | Director | 119,094,026 | — |
| — | Director | 30,090,979 | — |
| — | Chief Executive Officer | 2,057,270 | — |
| — | Chief Executive Officer | 1,814,643 | — |
| — | See Remarks | 727,177 | — |
| — | Chief Financial Officer | 674,636 | — |
| — | See Remarks | 606,791 | — |
| — | See Remarks | 425,318 | — |
| — | Chief Financial Officer | 423,486 | — |
| — | Director | 412,183 | — |
| — | See Remarks | 369,183 | — |
| — | General Counsel | 360,767 | — |
| — | Director | 311,200 | — |
| — | See Remarks | 302,072 | — |
| — | Director | 216,200 | — |
| — | Director | 205,478 | — |
| — | Director | 199,907 | — |
| — | Director | 184,348 | — |
| — | Director | 184,348 | — |
| — | Director | 184,348 | — |
| — | Director | 154,607 | — |
| — | Director | 138,055 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MRVI quote page; the site-wide leaderboard is on the insider transactions hub.